Canagliflozin
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Canagliflozin and local guidelines before prescribing.
SGLT2 inhibitor
Mechanism
SGLT2 inhibitor.
Uses
Type 2 diabetes.
Dosing
- Examples: Dapagliflozin 10 mg, empagliflozin 10 mg (25 mg for extra glucose lowering), canagliflozin 100–300 mg, ertugliflozin - once daily.
Endocrinology: Diabetes
Side effects
Genital infection, volume depletion, ketoacidosis, amputation risk (lower limb), fracture.
Interactions
Diuretics volume depletion; insulin hypoglycaemia.
Contraindications and cautions
Ketoacidosis, peripheral vascular disease caution
Monitoring
eGFR, ketones if unwell, feet
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Less effective at low eGFR
Overdose and reversal
Supportive
Special advice
Foot checks; sick-day rules.
More from the textbook: uses, cautions and other points
- Examples - dapagliflozin, empagliflozin, canagliflozin, ertugliflozin.
Endocrine: Anatomy Physiology and Pharmacology - Canagliflozin - possible increased risk of lower limb amputation (check feet).
Endocrine: Anatomy Physiology and Pharmacology
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (2 mentions)
- Endocrinology: Diabetes (1 mention)